A comparative trial use of sulpiride and risperidone in Huntington's disease: A pilot study

Journal of Psychopharmacology

Volumn 10, Issue 2, 1996, Pages 162-165

  Reveley, M A ^a,b   Dursun, S M ^a   Andrews, H ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Actometer; AIMs; Case report; Functional disability; Huntington's disease; Risperidone; Sulpiride

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE; SULPIRIDE;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL TRIAL; DYSKINESIA; FEMALE; FUNCTIONAL DISEASE; HUMAN; HUNTINGTON CHOREA; MALE; PHYSICAL DISABILITY; PRIORITY JOURNAL;

EID: 0029936269     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119601000213     Document Type: Article

References (13)

1. Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1986) Neuroleptic-induced extrapyramidal side-effects: clinical perspectives with ritanserin (R 55 667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 40: 492-499
2. Dursun S M, Andrews H, Reveley M A (1994) Computerised continuous assessment of abnormal involuntary movements in Huntingtons disease; improvement by sulpiride. Br J Clin Pharmacol 37: 503P-504P
3. Gower A J (1992) 5-HT receptors and cognitive function. In Marsden C A, Heal D J (eds), Central serotonin receptors and psychotropic drugs. Blackwell Scientific Publishers, pp. 239-259
4. Harper P S (1991) Huntington's disease. Major problems in neurology 22. Saunders, London
5. He H, Richardson J S (1995) A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol 10: 19-30
6. National Institute of Mental Health, Abnormal Involuntary Movement Scale (AIMs) (1976) In Guy O O (ed.), ECDEU assessment manual for psychopharmacology. Rockville, MD, US Department of Health, Education, and Welfare, p. 534
7. Quinn N, Marsden C D (1984) A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatr 47: 844-847
8. Reveley M A, Dursun S M, Andrews H (1993) Abnormal saccadic eye movements in Huntington's disease and the effects of a trial use of sulpiride. J Psychopharmacol Suppl A75
9. Reveley M A, Dursun S M, Andrews H (1994) Improvement of abnormal saccadic eye movements in Huntingdon's disease by sulpiride: a case study. J Psychopharmacol 8: 262-265
10. Reyntjens A, Gelders Y G, Hoppenbrouwers M L J A, Vanden Bussche G (1986) Thymosthenic effects of ritanserin (R 55 667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 8: 205-211
11. Shoulson I (1981) Huntington's disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 31: 1333-1335
12. Tryon W W (1991) Activity measurement in psychology and medicine. Plenum Press, New York
13. Vinar O, Molcan J, Nahunek K, Svestka J, Zapletalek M (1989) Ritanserin in schizophrenic patients. Act Nerv Super 31: 107-109